Drugs / Autologous Bone Marrow CD34+ Stem Cells
Autologous Bone Marrow CD34+ Stem Cells
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03981549 Comparator | Oct 2019 → Nov 2023 | central retinal vein occlusion | The Emmes Company, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Bone Marrow CD34+ Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03981549 ↗ |
| Modality | Cell therapy | “intravitreal autologous CD34+ stem cell therapy” NCT03981549 ↗ |
| Route | Intravitreal | “Single intravitreal injection of autologous bone marrow CD34+ stem cells.” NCT03981549 ↗ |